Want to see SKYE full AI Analyst Report?
Skye Bioscience (SKYE) Stock Statistics & Valuation Metrics
Total Valuation
Skye Bioscience has a market cap or net worth of $5.67M. The enterprise value is $17.63M.
- Market Cap
- $5.67M
- Enterprise Value
- $17.63M
Share Statistics
Skye Bioscience has 4,427,574 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 4,427,574
- Owned by Insiders
- 88.08%
- Owned by Institutions
- 1.11%
Financial Efficiency
Skye Bioscience’s return on equity (ROE) is -2.79 and return on invested capital (ROIC) is -286.55%.
- Return on Equity (ROE)
- -2.79
- Return on Assets (ROA)
- -1.98
- Return on Invested Capital (ROIC)
- -286.55%
- Return on Capital Employed (ROCE)
- -2.89
- Revenue Per Employee
- 0
- Profits Per Employee
- -27.96M
- Employee Count
- 2
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Skye Bioscience is -0.13. Skye Bioscience’s PEG ratio is 0.01.
- PE Ratio
- -0.13
- PS Ratio
- 0.00
- PB Ratio
- -13.17
- Price to FCF
- -0.15
- Price to Operating Cash Flow
- -0.17
- PEG Ratio
- 0.01
Income Statement
In the last 12 months, Skye Bioscience had revenue of 0 and earned -55.92M in profits. Earnings per share was -11.28.
- Revenue
- 0
- Gross Profit
- -723.35K
- Operating Income
- -58.16M
- Pretax Income
- -55.92M
- Net Income
- -55.92M
- EBITDA
- -55.20M
- Earnings Per Share (EPS)
- -11.28
Cash Flow
In the last 12 months, operating cash flow was -38.81M and capital expenditures -11, giving a free cash flow of -38.81M billion.
- Operating Cash Flow
- -38.81M
- Free Cash Flow
- -38.81M
- Free Cash Flow per Share
- -7.82
Dividends & Yields
Skye Bioscience pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -649.29%
- Earnings Yield
- -754.04%
Stock Price Statistics
- Beta
- 3.50
- 52-Week Price Change
- -89.35%
- 50-Day Moving Average
- 1.72
- 200-Day Moving Average
- 4.78
- Relative Strength Index (RSI)
- 33.78
- Average Volume (3m)
- 90.93K
Important Dates
Skye Bioscience upcoming earnings date is Nov 05, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 14, 2026
- Next Earnings Date
- Nov 05, 2026
- Ex-Dividend Date
- ―
Financial Position
Skye Bioscience as a current ratio of 3.30, with Debt / Equity ratio of 1.37%
- Current Ratio
- 3.30
- Quick Ratio
- 3.30
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.10
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Skye Bioscience has paid 5,400 in taxes.
- Income Tax
- 5,400
- Effective Tax Rate
- -0.00
Enterprise Valuation
Skye Bioscience EV to EBITDA ratio is 0.04, with an EV/FCF ratio of 0.05.
- EV to Sales
- 0.00
- EV to EBITDA
- 0.04
- EV to Free Cash Flow
- 0.05
- EV to Operating Cash Flow
- 0.05
Balance Sheet
Skye Bioscience has $10.06M in cash and marketable securities with $35.70K in debt, giving a net cash position of $10.03M billion.
- Cash & Marketable Securities
- $10.06M
- Total Debt
- $35.70K
- Net Cash
- $10.03M
- Net Cash Per Share
- $2.26
- Tangible Book Value Per Share
- -$0.10
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Skye Bioscience is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- -19.07%
Scores
- Smart Score
- ―
- AI Score
- 43
